JP2012143232A5 - - Google Patents

Download PDF

Info

Publication number
JP2012143232A5
JP2012143232A5 JP2012021947A JP2012021947A JP2012143232A5 JP 2012143232 A5 JP2012143232 A5 JP 2012143232A5 JP 2012021947 A JP2012021947 A JP 2012021947A JP 2012021947 A JP2012021947 A JP 2012021947A JP 2012143232 A5 JP2012143232 A5 JP 2012143232A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
seq
monoclonal antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012021947A
Other languages
English (en)
Japanese (ja)
Other versions
JP5420688B2 (ja
JP2012143232A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012021947A priority Critical patent/JP5420688B2/ja
Priority claimed from JP2012021947A external-priority patent/JP5420688B2/ja
Publication of JP2012143232A publication Critical patent/JP2012143232A/ja
Publication of JP2012143232A5 publication Critical patent/JP2012143232A5/ja
Application granted granted Critical
Publication of JP5420688B2 publication Critical patent/JP5420688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012021947A 2005-12-20 2012-02-03 抗ilt7抗体 Active JP5420688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012021947A JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
JP2005366465 2005-12-20
JP2012021947A JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007551124A Division JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体

Publications (3)

Publication Number Publication Date
JP2012143232A JP2012143232A (ja) 2012-08-02
JP2012143232A5 true JP2012143232A5 (enExample) 2013-04-25
JP5420688B2 JP5420688B2 (ja) 2014-02-19

Family

ID=38188642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007551124A Active JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体
JP2012021947A Active JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007551124A Active JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体

Country Status (29)

Country Link
US (6) US8084585B2 (enExample)
EP (4) EP3441403A1 (enExample)
JP (2) JP5020828B2 (enExample)
KR (3) KR101526934B1 (enExample)
CN (5) CN120718150A (enExample)
AU (1) AU2006328470B2 (enExample)
BR (1) BRPI0620141B1 (enExample)
CA (2) CA2994756C (enExample)
CY (3) CY1114227T1 (enExample)
DK (3) DK2532681T3 (enExample)
ES (3) ES2526079T3 (enExample)
HK (1) HK1218126A1 (enExample)
HR (2) HRP20130494T1 (enExample)
HU (1) HUE039865T2 (enExample)
IL (1) IL192266A (enExample)
LT (1) LT2913343T (enExample)
ME (1) ME02111B (enExample)
MX (1) MX2008007682A (enExample)
NZ (3) NZ599683A (enExample)
PL (3) PL2532681T3 (enExample)
PT (3) PT2913343T (enExample)
RS (2) RS53752B1 (enExample)
RU (2) RU2456298C2 (enExample)
SG (2) SG170749A1 (enExample)
SI (3) SI1964852T1 (enExample)
TR (1) TR201816574T4 (enExample)
UA (1) UA97946C2 (enExample)
WO (1) WO2007072866A1 (enExample)
ZA (1) ZA200805850B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
US9096660B2 (en) 2010-04-26 2015-08-04 Abraxis Bioscience, Llc SPARC binding antibodies and uses thereof
ES2661466T3 (es) 2011-04-01 2018-04-02 Immunogen, Inc. Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1
EP3575311A1 (en) 2012-03-20 2019-12-04 Biogen MA Inc. Jcv neutralizing antibodies
DK2828292T3 (da) 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
CN111499755A (zh) * 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
KR20170128256A (ko) * 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
SMT202100092T1 (it) * 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2016355206A1 (en) * 2015-11-19 2018-05-24 Abbvie Stemcentrx Llc Novel anti-EMR2 antibodies and methods of use
WO2017130060A1 (en) 2016-01-26 2017-08-03 Ciriello Christopher John Automated dental treatment system
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
RU2756275C2 (ru) * 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Антитела, специфические к рецептору полиовируса (pvr) человека
JP6979976B2 (ja) * 2016-03-10 2021-12-15 ヴィエラ バイオ,インコーポレーテッド Ilt7結合分子及びその使用方法
AU2017246794B2 (en) 2016-04-04 2024-07-04 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
JP2020536495A (ja) 2017-08-30 2020-12-17 フェインズ セラピューティクス,インコーポレーテッド 抗lag−3抗体及びその使用
CN111527105B (zh) 2017-10-11 2024-10-25 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
JP7194481B2 (ja) * 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物3(ilt3)に特異的な抗体およびその使用
US11396538B2 (en) 2017-12-20 2022-07-26 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof
WO2019141092A1 (zh) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
AU2019266407A1 (en) 2018-05-10 2021-01-07 Cyberdontics (Usa), Inc. Automated dental drill
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
KR20220082007A (ko) 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
IL293572A (en) * 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
TWI900560B (zh) 2020-04-20 2025-10-11 美商健臻公司 人類化抗補體因子bb抗體及其用途
JP2023537396A (ja) * 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ilt2に対する抗体およびその使用
CN116801810A (zh) 2020-09-03 2023-09-22 网络牙科(美国)公司 用于牙齿解剖结构的cna分析的方法和装置
MX2023013015A (es) * 2021-05-04 2023-11-15 Viela Bio Inc Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).
WO2024026388A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
EP4680344A1 (en) * 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
US20240366319A1 (en) 2023-05-04 2024-11-07 Perceptive Technologies, Inc. Robotic Dental System and Method of Preparing for a Robotic Dental Procedure
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN122080215A (zh) * 2023-12-05 2026-05-26 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其应用和产品
TW202607041A (zh) * 2024-06-27 2026-02-16 大陸商無錫徠特康生物科技有限公司 靶向ilt7和cd89的髓細胞銜接子抗體及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20040241167A1 (en) * 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
PL369953A1 (en) * 2001-10-13 2005-05-02 Asterion Limited Glycosylphosphatidylinositol containing polypeptides
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
WO2004013325A1 (ja) 2002-08-01 2004-02-12 Ginkgo Biomedical Research Institute Co., Ltd. マウスインターフェロン産生細胞の検出方法
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Similar Documents

Publication Publication Date Title
JP2018536393A5 (enExample)
JP2014526898A5 (enExample)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2017114866A5 (enExample)
JP2020536488A5 (enExample)
JP2013538057A5 (enExample)
JP2012501669A5 (enExample)
JP2014516540A5 (enExample)
JP2014524733A5 (enExample)
JP2011527899A5 (enExample)
JP2021500916A5 (enExample)
JP2014534207A5 (enExample)
JP2012501670A5 (enExample)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
JP2020501532A5 (enExample)
JP2016026303A5 (enExample)
JP2014518883A5 (enExample)
JP2012012402A5 (enExample)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2016516400A5 (enExample)
RU2017107773A (ru) Антитела, специфичные к ммр9
JP2017508475A5 (enExample)
JP2014511680A5 (enExample)
RU2019129917A (ru) Химерный антигенный рецептор